ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer

Anticancer Res. 2014 Jan;34(1):393-9.


Aim: The purpose of the present study was to investigate the possible association between Excision repair cross-complementing group 1 (ERCC1) score and platinum resistance in first-line chemotherapy for ovarian cancer.

Patients and methods: ERCC1 Expression was determined using immunohisto-chemistry in 68 patients with platinum-responding tumor and 30 with platinum-resistant tumors. The primary end-point of this study was the association between the expression of ERCC1 protein with resistance to standard platinum-based chemotherapy in primary ovarian cancer.

Results: In pairwise comparisons, the overall survival (OS) for patients with ovarian cancer, who were non-responders to platinum-based chemotherapy with low or intermediate H-score for ERCC1 was better than that of non-responders with high H-score for ERCC1 [median OS=21 (16.8-25.2 months) and 28 (14.6-41.4 months) vs. 15 months (6.2-23.8 months), p-value=0.048, and p-value=0.017, respectively].

Conclusion: There were no significant differences in the progression-free survival between those with low, intermediate and high H-score for ERCC1. There is no statistically significant relationship between ERCC1 score and response to platinum-based chemotherapy in patients with primary ovarian cancer.

Keywords: ERCC1 expression; Epithelial ovarian cancer; immunohistochemistry staining; platinum based chemotherapy.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / metabolism*
  • Carboplatin / administration & dosage
  • Carcinoma, Papillary / drug therapy
  • Carcinoma, Papillary / metabolism
  • Carcinoma, Papillary / mortality*
  • Cisplatin / administration & dosage
  • Cystadenocarcinoma, Serous / drug therapy
  • Cystadenocarcinoma, Serous / metabolism
  • Cystadenocarcinoma, Serous / mortality*
  • DNA-Binding Proteins / metabolism*
  • Drug Resistance, Neoplasm*
  • Endonucleases / metabolism*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoenzyme Techniques
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / mortality*
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Young Adult


  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • Carboplatin
  • ERCC1 protein, human
  • Endonucleases
  • Cisplatin